



# Figure S1

## A Cohort overview



## B Total number of samples



## C Overview of microbial stimulations

Experiment	Time	Stimulus	Concentration	Strain/Manufacturer
Whole blood	48 h	RPMI (1640 Dutch Modified)	-	Life Technologies
		LPS	100 ng/ml	<i>E. coli</i> /Sigma
		<i>C. albicans</i> conidia	1x10 <sup>9</sup> /mL	UC820
		<i>Staphylococcus aureus</i>	1x10 <sup>6</sup> /mL	ATCC29213
PBMC	24 h	LPS	100 ng/ml	<i>E. coli</i> /Sigma
		RPMI + Serum	10% human serum	Life Technologies
		RPMI	-	Life Technologies
		<i>C. albicans</i> conidia	1x10 <sup>9</sup> /mL	UC820
		<i>C. albicans</i> hyphae	1x10 <sup>6</sup> /mL	UC820
		<i>Staphylococcus aureus</i>	1x10 <sup>6</sup> /mL	ATCC29213
	7 d	<i>Bacteroides fragilis</i>	1x10 <sup>9</sup> /mL	ATCC25285
		RPMI + Serum	10%	Life Technologies
		<i>C. albicans</i> conidia	1x10 <sup>9</sup> /mL	UC820
		<i>C. albicans</i> hyphae	1x10 <sup>6</sup> /mL	UC820
		<i>Staphylococcus aureus</i>	1x10 <sup>6</sup> /mL	ATCC29213
		<i>Bacteroides fragilis</i>	1x10 <sup>9</sup> /mL	ATCC25285

## D Comparison of 500FG and LL-DEEP cohorts

